MX2021005876A - Elacestrant en combinacion con abemaciclib en mujeres con cancer de mama. - Google Patents
Elacestrant en combinacion con abemaciclib en mujeres con cancer de mama.Info
- Publication number
- MX2021005876A MX2021005876A MX2021005876A MX2021005876A MX2021005876A MX 2021005876 A MX2021005876 A MX 2021005876A MX 2021005876 A MX2021005876 A MX 2021005876A MX 2021005876 A MX2021005876 A MX 2021005876A MX 2021005876 A MX2021005876 A MX 2021005876A
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- elacestrant
- abemaciclib
- combination
- women
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente descripción se refiere a métodos para tratar el cáncer de mama en un paciente, que comprenden administrar al paciente una combinación terapéutica que comprende elacestrant, o una sal farmacéuticamente aceptable del mismo, y abemaciclib, o una sal farmacéuticamente aceptable del mismo. La presente descripción también se refiere a métodos para tratar el cáncer de mama en un paciente, que producen un tiempo de supervivencia libre de progresión más prolongado en comparación con otros tratamientos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773960P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/063239 WO2020112765A1 (en) | 2018-11-30 | 2019-11-26 | Elacestrant in combination with abemaciclib in women with breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005876A true MX2021005876A (es) | 2021-07-16 |
Family
ID=68966023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005876A MX2021005876A (es) | 2018-11-30 | 2019-11-26 | Elacestrant en combinacion con abemaciclib en mujeres con cancer de mama. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220117963A1 (es) |
| EP (1) | EP3886826A1 (es) |
| JP (1) | JP2022509262A (es) |
| KR (1) | KR20210097170A (es) |
| CN (1) | CN113164415A (es) |
| AU (1) | AU2019388900A1 (es) |
| BR (1) | BR112021010169A2 (es) |
| CA (1) | CA3120368A1 (es) |
| EA (1) | EA202191165A1 (es) |
| IL (1) | IL283502A (es) |
| MA (1) | MA54293A (es) |
| MX (1) | MX2021005876A (es) |
| PH (1) | PH12021551235A1 (es) |
| SG (1) | SG11202105455RA (es) |
| WO (1) | WO2020112765A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL303041A (en) * | 2020-11-23 | 2023-07-01 | Sanofi Sa | Combinations containing abamciclib, and 6-(2,4-DICHLOROPHENYL)-5-[4-[(3S)-1-(3-FLUOROPROPYL)PYRROLIDIN-3-YL]OXYPHENYL]-8,9-DIHYDRO-7H-BENZO [7]ANNULENE-2-CARBOXYLIC ACID |
| CN114146182A (zh) * | 2021-11-12 | 2022-03-08 | 深圳大学 | Cdk4/6抑制剂与铂类化疗药物在制备治疗肿瘤的药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016256470B2 (en) * | 2015-04-29 | 2020-10-15 | Radius Pharmaceuticals, Inc. | Methods of treating cancer |
| MX2018011054A (es) * | 2016-03-15 | 2019-01-21 | Merrimack Pharmaceuticals Inc | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. |
| WO2018017410A1 (en) * | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer |
-
2019
- 2019-11-26 JP JP2021530913A patent/JP2022509262A/ja active Pending
- 2019-11-26 CA CA3120368A patent/CA3120368A1/en active Pending
- 2019-11-26 AU AU2019388900A patent/AU2019388900A1/en active Pending
- 2019-11-26 KR KR1020217020321A patent/KR20210097170A/ko unknown
- 2019-11-26 US US17/298,198 patent/US20220117963A1/en active Pending
- 2019-11-26 EA EA202191165A patent/EA202191165A1/ru unknown
- 2019-11-26 BR BR112021010169-1A patent/BR112021010169A2/pt unknown
- 2019-11-26 WO PCT/US2019/063239 patent/WO2020112765A1/en active Application Filing
- 2019-11-26 MA MA054293A patent/MA54293A/fr unknown
- 2019-11-26 MX MX2021005876A patent/MX2021005876A/es unknown
- 2019-11-26 SG SG11202105455RA patent/SG11202105455RA/en unknown
- 2019-11-26 EP EP19824087.1A patent/EP3886826A1/en active Pending
- 2019-11-26 CN CN201980079089.6A patent/CN113164415A/zh active Pending
-
2021
- 2021-05-27 IL IL283502A patent/IL283502A/en unknown
- 2021-05-28 PH PH12021551235A patent/PH12021551235A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL283502A (en) | 2021-07-29 |
| EP3886826A1 (en) | 2021-10-06 |
| EA202191165A1 (ru) | 2021-09-21 |
| KR20210097170A (ko) | 2021-08-06 |
| CN113164415A (zh) | 2021-07-23 |
| MA54293A (fr) | 2021-10-06 |
| BR112021010169A2 (pt) | 2021-08-17 |
| JP2022509262A (ja) | 2022-01-20 |
| WO2020112765A1 (en) | 2020-06-04 |
| PH12021551235A1 (en) | 2021-12-13 |
| AU2019388900A1 (en) | 2021-06-10 |
| US20220117963A1 (en) | 2022-04-21 |
| CA3120368A1 (en) | 2020-06-04 |
| SG11202105455RA (en) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500845A1 (en) | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof | |
| MX2018001659A (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
| MX2024010140A (es) | Nuevos metodos. | |
| PH12019500892A1 (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
| MY186977A (en) | Tetrasubstituted alkene compounds and their use | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| WO2016043874A3 (en) | Combination therapy for treating cancer | |
| MX2021002322A (es) | Nuevos metodos. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2019009190A (es) | Uso de gaboxadol en el tratamiento de tinnitus. | |
| MX2019015207A (es) | Compuestos para tratar el cancer de ovario. | |
| PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
| MX2022000143A (es) | Metodos novedosos. | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| MX2024005453A (es) | Composiciones y tratamientos con nirogacestat. | |
| MX2022003190A (es) | Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. | |
| MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| MX2021006778A (es) | Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion. | |
| MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. |